← Back to Search

Enlicitide Decanoate for High Cholesterol

Phase 3
Recruiting
Research Sponsored by Merck Sharp & Dohme LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Has an ongoing serious adverse event considered related to study intervention by the investigator in the parent study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 3 years
Awards & highlights

Summary

This trial is looking at the safety and effectiveness of enlicitide decanoate in adults with high cholesterol who previously participated in other studies.

Who is the study for?
This trial is for adults with high cholesterol who have already completed one of the earlier enlicitide decanoate studies (MK-0616-013, MK-0616-017, or MK-0616-018). Specific eligibility details are not provided but typically include meeting certain health standards and previous study participation.
What is being tested?
The trial is testing the long-term safety and effectiveness of a drug called Enlicitide Decanoate in managing high cholesterol. This extension study follows up on participants from prior related trials to gather more data over a longer period.
What are the potential side effects?
While specific side effects are not listed here, common ones associated with PCSK9 inhibitors like Enlicitide may include injection site reactions, cold-like symptoms, and possibly muscle pain. Individual experiences can vary.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am experiencing a serious side effect from a previous study treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants who discontinue study drug due to an AE
Number of participants with one or more adverse events (AEs)
Secondary outcome measures
Mean percent change from baseline of the parent study in LDL-C at Week 8 of this extension study
Mean percent change from baseline of the parent study in apolipoprotein B (ApoB) at Week 8 of this extension study
Mean percent change from baseline of the parent study in non-high-density lipoprotein cholesterol (non-HDL-C) at Week 8 of this Extension Study
+3 more

Side effects data

From 2022 Phase 2 trial • 381 Patients • NCT05261126
7%
Dyspepsia
5%
Arthralgia
4%
Fatigue
1%
COVID-19
1%
Nausea
1%
Cholecystitis
1%
Diarrhoea
1%
Deep vein thrombosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
MK-0616 12 mg
MK-0616 18 mg
MK-0616 30 mg
Placebo
MK-0616 6 mg

Trial Design

1Treatment groups
Experimental Treatment
Group I: Enlicitide DecanoateExperimental Treatment1 Intervention
Participants will receive 20 mg of enlicitide decanoate orally once daily (QD)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enlicitide Decanoate
2023
Completed Phase 2
~420

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCLead Sponsor
3,950 Previous Clinical Trials
5,171,983 Total Patients Enrolled
5 Trials studying High Cholesterol
14,762 Patients Enrolled for High Cholesterol
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,834 Previous Clinical Trials
8,076,780 Total Patients Enrolled
2 Trials studying High Cholesterol
14,583 Patients Enrolled for High Cholesterol
~2000 spots leftby Oct 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top